Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJ37UX)

Drug Name
Revacept Drug Info
Synonyms Arterial thrombosis treatment, Trigen; PR-15; Antiplatelet protein therapy (arterial thrombosis/atherosclerosis), Trigen
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMJ37UX

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet glycoprotein VI (GP6) TTTJUVZ GPVI_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Platelet glycoprotein VI (GP6) DTT GP6 5.731 5.24 4.888 6.127
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Arteriosclerosis
ICD Disease Classification BD40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Platelet glycoprotein VI (GP6) DTT GP6 3.57E-01 0.03 0.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01645306) Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02). U.S. National Institutes of Health.
2 Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation.2011 May 3;123(17):1891-9.